Thea Pharma’s Iyuzeh Receives the US FDA’s Approval for Open-Angle Glaucoma or Ocular Hypertension
Shots:
- The US FDA has approved the NDA of Iyuzeh (latanoprost ophthalmic solution) 0.005% for the reduction of elevated IOP in patients with OAG or ocular hypertension (OHT). Iyuzeh is expected to be available for US eyecare practitioners in H2’23
- The clinical trials results showed that Iyuzeh lowered IOP by 3-8 mmHg vs 4-8mmHg with latanoprost ophthalmic solution (Xalatan; Viatris) 0.005%, which contains benzalkonium chloride in patients with open-angle glaucoma or ocular hypertension with a mean baseline IOP of 19-24mmHg
- Iyuzeh is the first preservative-free formulation of latanoprost in the US that reduces IOP ~3-4 hrs. after administration with a maximum effect observed after 8-12hrs.
Ref: Thea Pharma | Image: Thea Pharma
Related News:- Thea and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
